Microbeam Irradiation as a Simultaneously Integrated Boost in a Conventional Whole-Brain Radiotherapy Protocol

Int J Mol Sci. 2022 Jul 28;23(15):8319. doi: 10.3390/ijms23158319.

Abstract

Microbeam radiotherapy (MRT), an experimental high-dose rate concept with spatial fractionation at the micrometre range, has shown a high therapeutic potential as well as good preservation of normal tissue function in pre-clinical studies. We investigated the suitability of MRT as a simultaneously integrated boost (SIB) in conventional whole-brain irradiation (WBRT). A 174 Gy MRT SIB was administered with an array of quasi-parallel, 50 µm wide microbeams spaced at a centre-to-centre distance of 400 µm either on the first or last day of a 5 × 4 Gy radiotherapy schedule in healthy adult C57 BL/6J mice and in F98 glioma cell cultures. The animals were observed for signs of intracranial pressure and focal neurologic signs. Colony counts were conducted in F98 glioma cell cultures. No signs of acute adverse effects were observed in any of the irradiated animals within 3 days after the last irradiation fraction. The tumoricidal effect on F98 cell in vitro was higher when the MRT boost was delivered on the first day of the irradiation course, as opposed to the last day. Therefore, the MRT SIB should be integrated into a clinical radiotherapy schedule as early as possible.

Keywords: F98 glioma cells; brain tissue tolerance; microbeam radiotherapy (MRT); simultaneously integrated boost (SIB).

MeSH terms

  • Animals
  • Brain / radiation effects
  • Brain Neoplasms* / radiotherapy
  • Dose Fractionation, Radiation
  • Glioma* / radiotherapy
  • Mice
  • Radiation Dosage
  • Synchrotrons